SHARE:   Share to Facebook Share to Twitter Share to Linked In Share via Email  

Back To Search Results

Emerging Science Session

Event Time: Tuesday April 25, 2017 5:45 pm to 7:15 pm
Topic(s): Child Neurology and Developmental Neurology, Epilepsy/Clinical Neurophysiology (EEG), Headache, Movement Disorders, MS and CNS Inflammatory Disease, Neuromuscular and Clinical Neurophysiology (EMG)
Director(s):
Description: A special session emphasizing ongoing neuroscience research of an extraordinary nature, which warrants expedited presentation. Key aspects of the research must have taken place after October 24, 2016.
Completion Message:
CME Credits: 1.5
Core Competencies:

Program Speakers - Tentative

Start/End Time Title Faculty
Currently there are no events in the timeline.

Disclosures

Speaker Disclosure

Abstract Presenters

Start Time Pub. Title Presenter
5:45 PM 001 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Erenumab in Migraine Prevention: Primary Results of the ARISE Trial David Dodick, MD, FAAN
Disclosure:
Dr. Dodick has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acorda, Allergan, Amgen, Alder, Dr Reddy’s, Merck, Dr Reddy’s, Promius, eNeura, Eli Lilly & Company, Insys therapeutics, Autonomic Technologies, Teva, Xenon, Tonix, Trigemina, Boston Scientific, GBS, Colucid, Zosano, Laydenburg Thalmann, Biocentric, Biohaven, Magellan, Pfizer (Japan), Charleston Laboratories. Royalties: Oxford University Press and Cambridge University Press (Book Royalty). Uptodate – editorial/honoraria. CME companies honoraria/publishing honoraria/royalites: Chameleon Communications, Medscape, WebMD, Academy for Continued Healthcare Learning, Haymarket Medical Education, Miller Medical Communications, Global Scientific Communications, HealthLogix, Academy for Continued Healthcare Learning, Meeting LogiX, Health LogiX, . Dr. Dodick has received compensation for serving on the Board of Directors of . Dr. Dodick holds stock and/or stock options in Nocira, Second Opinion, .

5:48 PM 002 Non-invasive Vagus Nerve Stimulation for the Acute Treatment of Episodic and Chronic Cluster Headache: Findings From the Randomized, Double-blind, Sham-Controlled ACT2 Study Peter Goadsby, MD, PhD
Disclosure:
Dr. Goadsby has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alder Biopharmaceuticals, Allergan, Amgen, Electrocore, Eli-Lilly, eNeura, Novartis, Teva. Dr. Goadsby has received personal compensation in an editorial capacity for Journal Watch, Up-to-Date, Oxford Univeristy Press, Massachusetts Medical Society, Walters Kluwer. Dr. Goadsby has received compensation for serving on the Board of Directors of Trigemina Inc. Dr. Goadsby has received research support from Amgen.

5:51 PM 003 Double-blind, randomized, placebo-controlled, Phase III study (TOLEDO) to evaluate the efficacy of apomorphine subcutaneous infusion in reducing OFF time in Parkinson’s disease patients with motor fluctuations not well controlled on optimized medical treatment Regina Katzenschlager
Disclosure:

5:54 PM 004 Intraputaminal AADC gene therapy for advanced Parkinson's disease: Interim Results of a Phase 1b Trial Chadwick Christine, MD
Disclosure:
Research support from Voyager Therapeutics.

5:57 PM 005 Motor effects and safety of IPX203, an investigational extended-release formulation of carbidopa-levodopa, in advanced Parkinson’s disease: A single-dose Phase 2 study Mark Stacy, MD, FAAN
Disclosure:
Consultation: Allergan, Avid, Best Doctors, Biotie, Eli Lilly, Lundbeck, Merz, Neuronova, Novartis Pharma (Japan), Osmotica, Pfizer, Saraepta Therapeutics, SK Life Sciences, Sunovion Pharmaceuticals, Inc. Advisory Boards: Benign Essential Blepharospasm . Editorial Board Member: Journal of Clinical Investigation (JCI). Informa Press for Handbook of Dystonia, Duke University for Wearing Off Questionnaire (WOQ). Grants: IMPAX, Pfizer, Pharma2B.

6:00 PM 006 RESULTS OF A PHASE 1 STUDY OF ABBV-8E12 IN PATIENTS WITH PROGRESSIVE SUPRANUCLEAR PALSY AND PHASE 2 STUDY DESIGN IN ALZHEIMER’S DISEASE AND PSP Hana Florian
Disclosure:

6:03 PM 007 Sustained seizure reduction with adjunctive everolimus for treatment-refractory seizures associated with tuberous sclerosis complex (TSC): Long-term results from the phase 3 EXIST-3 study David Franz, MD
Disclosure:
I have received travel support and honoraria from Novartis. My employer has received payments for research studies conducted at CCHMC and for consulting work I have done from Novartis as well.. Support for other research at his institution from Novartis.

6:06 PM 008 Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a dose-ranging, multi-center, randomized, double-blind, placebo-controlled trial (GWPCARE3) Anup Patel, MD
Disclosure:
GW Pharmaceuticals and Liva Nova - Consulting Supernus - Scientific Advisory Board UCB Pharma - Scientific advisory board . GW Pharmaceuticals - Research Grant Upsher Smith - Research Grant Pediatric Epilepsy Research Foundation - Research Grant Brain Sentinel - Research Grant .

6:09 PM 009 Efficacy and safety of nusinersen in children with later-onset spinal muscular atrophy (SMA): interim results of the phase 3 CHERISH study Richard Finkel, MD
Disclosure:
Grants and personal fees from Ionis Pharmaceuticals during ENDEAR and CHERISH; grants and advisor fees from Biogen, grants from Cytokinetics and advisor to Roche outside the submitted work; advisory capacity to non-profit organizations: the SMA Foundation, Cure SMA, SMA Reach (UK) and SMA Europe; serves on the Data Safety Monitoring Board for the AveXis gene transfer study... Grants and personal fees from Ionis Pharmaceuticals during ENDEAR, CHERISH; grants and advisor fees from Biogen, grants from Cytokinetics and advisor to Roche outside the submitted work; serves on the Data Safety Monitoring Board for the AveXis gene transfer study..

6:12 PM 010 Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (CIDP), a multicenter randomized double-blind placebo-controlled trial: the PATH Study Ivo Van Schaik, MD
Disclosure:
Dr. van Schaik I.S. chairs a steering committee for CSL-Behring and received departmental honoraria for serving on scientific advisory boards for CSL-Behring, Baxalta and UCB. He received speakers fees from CSL-Behring and Kedrion. .

6:15 PM 011 Results of a Phase 1b/2 Study of ATYR1940 in Adult Patients with Limb Girdle Muscular Dystrophy Type 2B (LGMD2B) and Facioscapulohumeral Muscular Dystrophy (FSHD) (ATYR1940-C-004) John Vissing, MD
Disclosure:
I have served on Advisory boards of Alexion Pharmaceuticals and Ultragenyx.

6:18 PM 012 Dual Responder Analyses of Both Muscle Strength and Activities of Daily Living, Eculizumab Versus Placebo, in Refractory Generalized Myasthenia Gravis (gMG) Patients: Results from the REGAIN Study James Howard, MD, FAAN
Disclosure:
Pfizer - family and self own stock as part of an overall portfolio;Johnson & Johnson - family and self own stock as part of an overall portfolio;General Electric - family and self own;. Alexion Pharmaceuticals: Research grant support for clinical trial support, payable to the University of North Carolina..

6:21 PM 013 Comparison of protein-coding and long, non-coding RNA gene expression signatures to classify multiple sclerosis Charles Spurlock, PhD
Disclosure:
Dr. Spurlock is co-founder and CEO of IQuity, Inc.. Dr. Spurlock is co-founder and CEO of IQuity, Inc.. Dr. Spurlock is co-founder and CEO of IQuity, Inc. IQuity has licensed technology from Vanderbilt University Medical Center where Dr. Spurlock serves on the faculty. . Dr. Spurlock is co-founder and CEO of IQuity, Inc.. Dr. Spurlock has received research support at Vanderbilt University Medical Center from Pfizer to support basic science research. .

6:24 PM 014 A ‘surface-in’ gradient of thalamic damage is an early and disease-specific process in pediatric-onset multiple sclerosis Giulia Fadda, MD
Disclosure:
Dr. Fadda has nothing to disclose.

Register Now

Related Courses

Monday April 23, 2018

7:00 AM-9:00 AM
C61 Therapy of Neuromuscular Disease: ALS, Inflammatory Neuropathies and Myopathies, and Myasthenia Gravis Michael Weiss MD, FAAN
C62 Child Neurology I: Pediatric Stroke, MS/Autoimmune Marc Patterson MD, FAAN, FRACP
C65 Video EEG: Name That Spell Amy Crepeau MD
C58 Balance and Gait Disorders Bastiaan Bloem MD, PhD
1:00 PM-3:00 PM
C67 Evaluating Tremor in the Office Vicki Shanker MD
C70 Child Neurology II: Epilepsy and Neuromuscular Marc Patterson MD, FAAN, FRACP
C71 Neuro-rheumatology: Neurological Manifestations of Systemic Inflammatory and Autoimmune Disease I Jeffrey Gelfand MD, MAS, FAAN
C73 Clinical Approach to Muscle Disease I: Role of Antibodies, Muscle Imaging and Genetic Testing Rhabdomyolysis Tahseen Mozaffar MD, FAAN
C76 Comprehensive Migraine Education Program I: Diagnosis, Risk Factors, and Neurobiology Gretchen Tietjen MD
C74 Epilepsy Surgery Update Stephan Schuele MD, FAAN
3:30 PM-5:30 PM
N2 Neuroscience in the Clinic: Antisense Oligonucleotide (ASO) Therapy John Day MD, PhD,
Richard Finkel MD
C85 Child Neurology III: Headache, TBI/Post-concussion Marc Patterson MD, FAAN, FRACP
C86 Neuro-rheumatology: Neurological Manifestations of Systemic Inflammatory and Autoimmune Disease II Jeffrey Gelfand MD, MAS, FAAN
C88 Clinical Approach to Muscle Disease II: Inflammatory Myopathies and Muscle Pathology Tahseen Mozaffar MD, FAAN
C89 Comprehensive Migraine Education Program II: Behavioral and Psychological Approaches, and Preventive and Acute Treatment Advances Gretchen Tietjen MD
C94 Spanish: Update CNS Infections and Tropical Medicine Oscar Del Brutto MD, FAAN

Thursday April 26, 2018

7:00 AM-9:00 AM
C178 Clinical EMG I: Principles and Practice of NCS and Needle EMG Ruple Laughlin MD, FAAN
C171 Clinical Epilepsy I: Basics Tracey Milligan MD, FAAN
C174 Clinical Pearls in Autoimmune Neurology: Real World Cases Stacey Clardy MD, PhD
C176 The Dystonia: Diagnosis, Treatment and Update on Etiologies Rachel Saunders-Pullman MD
1:00 PM-3:00 PM
N5 Neuroscience in the Clinic: Treatment of Progressive Multiple Sclerosis Eric Klawiter MD,
Ellen Mowry MD, FAAN
C191 Clinical EMG II: Neuromuscular Junction Testing and Quantitative EMG Mark Bromberg MD, PhD, FAAN
C181 Clinical Epilepsy II: Considerations Across the Age Span Pediatrics, Pregnancy, and Elderly Barbara Jobst MD, FAAN
C186 Cerebellar and Afferent Ataxias: Diagnosis and Management Massimo Pandolfo MD, FAAN
C193 Practical Training in Injection Techniques in the Treatment of Headache Disorders Skills Workshop Morris Levin MD, FAAN
3:30 PM-5:30 PM
C205 Clinical EMG III: Nerve Conduction Criteria and Electrodiagnostic Approaches Mark Bromberg MD, PhD, FAAN
C196 Clinical Epilepsy III: Advanced (Status, Beyond AED, Video EEG) Tobias Loddenkemper MD
C208 Clinical Usefulness of Botulinum Toxin for Spasticity Skills Workshop Allison Brashear MD, MBA, FAAN
6:30 PM-9:30 PM
C209 Case Studies: Unusual Diagnostic and Management of Cases in Neuromuscular Disease Anne Connolly MD, FAAN
C212 Case Studies: Unusual Movement Disorders Kailash Bhatia MD, FAAN
C213 Case Studies: Challenging Headache Cases Kathleen Digre MD, FAAN

MEMBER LOG IN

Forgot Password?